Iladatuzumab Biosimilar - Research Grade

Human

CD79B

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD79b (HM79b) In Vivo Antibody - Low Endotoxin (ICH1265), Polatuzumab Biosimilar - Research Grade (ICH5039)

https://www.imgt.org/mAb-DB/

ICH3002

P40259

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of iladatuzumab, an anti-CD79B monoclonal antibody originally developed as the antibody component of an antibody-drug conjugate. It is a research-grade human IgG1 (kappa) reagent built around the CD79B target and is intended strictly for research use only; it is not the clinical drug and is not for human or veterinary use. Because it reproduces the target-binding specificity of the originator without a cytotoxic payload or therapeutic formulation, it is useful as a defined tool for probing CD79B on normal and malignant B cells. Typical applications include serving as a positive or isotype-matched binding control, epitope and antigen-expression studies, ADCC/ADCP assay setup, and as a naked antibody backbone for in-house antibody-drug conjugate development and payload-conjugation chemistry. It is offered in low-endotoxin grades (research grade below 1 EU/mg; ultra-low below 0.5 EU/mg) suitable for sensitive cell-based work, and is available in bulk milligram-to-gram quantities to support assay development, screening campaigns, and preclinical characterization. Guidance provided here is for ichorbio to review. CD79B (Ig-beta, B29; UniProt P40259) is a transmembrane signaling subunit of the B-cell antigen receptor (BCR) complex. Together with its partner CD79A (Ig-alpha), it forms a disulfide-linked heterodimer that non-covalently associates with membrane immunoglobulin; the mIg provides antigen recognition while the CD79A/CD79B heterodimer transduces the signal. Each cytoplasmic tail carries an immunoreceptor tyrosine-based activation motif (ITAM) that becomes phosphorylated by SRC-family and SYK kinases upon antigen engagement, initiating downstream signaling that drives B-cell development, activation, and survival. CD79B is required for surface BCR assembly and export, and its expression is largely restricted to the B lineage from pro-B through mature B cells, with loss at terminal plasma-cell differentiation. This B-cell-restricted, internalizing surface expression, retained on many B-cell non-Hodgkin lymphomas, makes CD79B an attractive target for antibody and antibody-drug-conjugate approaches.

B-cell-specific glycoprotein B29, Ig-beta, Immunoglobulin-associated B29 protein, B-cell antigen receptor complex-associated protein beta chain, B29, IGB

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Iladatuzumab biosimilar available in bulk or gram quantities?

A: Yes — the Iladatuzumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Iladatuzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Iladatuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Iladatuzumab that binds CD79B.